SemEval-2024 Task 2: Safe Biomedical Natural Language Inference for Clinical Trials
2404.04963
0
0
Abstract
Large Language Models (LLMs) are at the forefront of NLP achievements but fall short in dealing with shortcut learning, factual inconsistency, and vulnerability to adversarial inputs.These shortcomings are especially critical in medical contexts, where they can misrepresent actual model capabilities. Addressing this, we present SemEval-2024 Task 2: Safe Biomedical Natural Language Inference for ClinicalTrials. Our contributions include the refined NLI4CT-P dataset (i.e., Natural Language Inference for Clinical Trials - Perturbed), designed to challenge LLMs with interventional and causal reasoning tasks, along with a comprehensive evaluation of methods and results for participant submissions. A total of 106 participants registered for the task contributing to over 1200 individual submissions and 25 system overview papers. This initiative aims to advance the robustness and applicability of NLI models in healthcare, ensuring safer and more dependable AI assistance in clinical decision-making. We anticipate that the dataset, models, and outcomes of this task can support future research in the field of biomedical NLI. The dataset, competition leaderboard, and website are publicly available.
Create account to get full access
Overview
- This paper introduces SemEval-2024 Task 2, which focuses on Safe Biomedical Natural Language Inference (NLI) for Clinical Trials.
- The task aims to develop natural language processing (NLP) models that can accurately and safely infer relationships between statements related to clinical trials.
- Key challenges include handling sensitive biomedical data, ensuring model faithfulness and consistency, and evaluating model behavior in safety-critical domains.
Plain English Explanation
The paper describes a new challenge in natural language processing (NLP) called SemEval-2024 Task 2, which is focused on Safe Biomedical Natural Language Inference for Clinical Trials. This task aims to develop NLP models that can understand the relationships between different statements about clinical trials, which are studies that test new medical treatments.
One key challenge is that the information involved in clinical trials is highly sensitive, as it deals with people's health and personal data. So the NLP models need to be able to handle this sensitive data safely and securely.
Another challenge is ensuring the models are "faithful" and "consistent" - meaning they behave in a reliable and predictable way, and don't make mistakes that could have serious consequences. Evaluating this is crucial, especially in safety-critical domains like healthcare.
The paper highlights the importance of faithfulness and consistency evaluation when developing these types of NLP models for real-world applications. This helps ensure the models are not just accurate, but also trustworthy and safe to use.
Technical Explanation
The paper introduces SemEval-2024 Task 2, which focuses on Safe Biomedical Natural Language Inference (NLI) for Clinical Trials. NLI is the task of determining the logical relationship (entailment, contradiction, or neutral) between two text snippets.
In this case, the task involves developing NLP models that can accurately and safely infer relationships between statements related to clinical trials. This is challenging due to the sensitive nature of the biomedical data involved, as well as the need to ensure the models behave in a faithful and consistent manner.
The paper highlights key challenges, including:
- Handling sensitive biomedical data in a safe and secure way
- Ensuring model faithfulness and consistency, especially in safety-critical domains
- Effectively evaluating model behavior and performance in these areas
The paper emphasizes the importance of faithfulness and consistency evaluation, as demonstrated in related work. Faithful and consistent models are crucial for real-world applications like clinical decision support, where mistakes could have serious consequences.
Critical Analysis
The paper provides a well-motivated introduction to the SemEval-2024 Task 2 challenge, highlighting the key difficulties in developing safe and reliable NLP models for clinical trial data. The emphasis on faithfulness and consistency evaluation is particularly important, as these properties are often overlooked in favor of raw accuracy metrics.
One potential limitation of the task is the reliance on human-annotated data, which can be expensive and time-consuming to produce. The authors may want to explore alternative approaches, such as leveraging existing clinical trial databases or using synthetic data generation techniques, to expand the available training data.
Additionally, the paper could have addressed potential ethical concerns more explicitly, such as the risks of model bias or misuse, and how these issues should be considered during model development and evaluation.
Overall, the SemEval-2024 Task 2 represents an important step in advancing the field of biomedical NLP and ensuring the safe deployment of these technologies in real-world clinical settings.
Conclusion
This paper introduces SemEval-2024 Task 2, which focuses on developing natural language processing (NLP) models that can accurately and safely infer relationships between statements related to clinical trials. The task highlights key challenges, such as handling sensitive biomedical data, ensuring model faithfulness and consistency, and effectively evaluating model behavior in safety-critical domains.
The emphasis on faithfulness and consistency evaluation is particularly crucial, as it helps ensure these models are not just accurate, but also trustworthy and safe to use in real-world applications like clinical decision support. By addressing these challenges, the task aims to advance the field of biomedical NLP and pave the way for the safe deployment of these technologies in healthcare.
This summary was produced with help from an AI and may contain inaccuracies - check out the links to read the original source documents!
Related Papers
IITK at SemEval-2024 Task 2: Exploring the Capabilities of LLMs for Safe Biomedical Natural Language Inference for Clinical Trials
Shreyasi Mandal, Ashutosh Modi
0
0
Large Language models (LLMs) have demonstrated state-of-the-art performance in various natural language processing (NLP) tasks across multiple domains, yet they are prone to shortcut learning and factual inconsistencies. This research investigates LLMs' robustness, consistency, and faithful reasoning when performing Natural Language Inference (NLI) on breast cancer Clinical Trial Reports (CTRs) in the context of SemEval 2024 Task 2: Safe Biomedical Natural Language Inference for Clinical Trials. We examine the reasoning capabilities of LLMs and their adeptness at logical problem-solving. A comparative analysis is conducted on pre-trained language models (PLMs), GPT-3.5, and Gemini Pro under zero-shot settings using Retrieval-Augmented Generation (RAG) framework, integrating various reasoning chains. The evaluation yields an F1 score of 0.69, consistency of 0.71, and a faithfulness score of 0.90 on the test dataset.
4/9/2024
SEME at SemEval-2024 Task 2: Comparing Masked and Generative Language Models on Natural Language Inference for Clinical Trials
Mathilde Aguiar, Pierre Zweigenbaum, Nona Naderi
0
0
This paper describes our submission to Task 2 of SemEval-2024: Safe Biomedical Natural Language Inference for Clinical Trials. The Multi-evidence Natural Language Inference for Clinical Trial Data (NLI4CT) consists of a Textual Entailment (TE) task focused on the evaluation of the consistency and faithfulness of Natural Language Inference (NLI) models applied to Clinical Trial Reports (CTR). We test 2 distinct approaches, one based on finetuning and ensembling Masked Language Models and the other based on prompting Large Language Models using templates, in particular, using Chain-Of-Thought and Contrastive Chain-Of-Thought. Prompting Flan-T5-large in a 2-shot setting leads to our best system that achieves 0.57 F1 score, 0.64 Faithfulness, and 0.56 Consistency.
4/8/2024
š¤Æ
D-NLP at SemEval-2024 Task 2: Evaluating Clinical Inference Capabilities of Large Language Models
Duygu Altinok
0
0
Large language models (LLMs) have garnered significant attention and widespread usage due to their impressive performance in various tasks. However, they are not without their own set of challenges, including issues such as hallucinations, factual inconsistencies, and limitations in numerical-quantitative reasoning. Evaluating LLMs in miscellaneous reasoning tasks remains an active area of research. Prior to the breakthrough of LLMs, Transformers had already proven successful in the medical domain, effectively employed for various natural language understanding (NLU) tasks. Following this trend, LLMs have also been trained and utilized in the medical domain, raising concerns regarding factual accuracy, adherence to safety protocols, and inherent limitations. In this paper, we focus on evaluating the natural language inference capabilities of popular open-source and closed-source LLMs using clinical trial reports as the dataset. We present the performance results of each LLM and further analyze their performance on a development set, particularly focusing on challenging instances that involve medical abbreviations and require numerical-quantitative reasoning. Gemini, our leading LLM, achieved a test set F1-score of 0.748, securing the ninth position on the task scoreboard. Our work is the first of its kind, offering a thorough examination of the inference capabilities of LLMs within the medical domain.
5/8/2024
Towards Safe Large Language Models for Medicine
Tessa Han, Aounon Kumar, Chirag Agarwal, Himabindu Lakkaraju
0
0
As large language models (LLMs) develop increasingly sophisticated capabilities and find applications in medical settings, it becomes important to assess their medical safety due to their far-reaching implications for personal and public health, patient safety, and human rights. However, there is little to no understanding of the notion of medical safety in the context of LLMs, let alone how to evaluate and improve it. To address this gap, we first define the notion of medical safety in LLMs based on the Principles of Medical Ethics set forth by the American Medical Association. We then leverage this understanding to introduce MedSafetyBench, the first benchmark dataset specifically designed to measure the medical safety of LLMs. We demonstrate the utility of MedSafetyBench by using it to evaluate and improve the medical safety of LLMs. Our results show that publicly-available medical LLMs do not meet standards of medical safety and that fine-tuning them using MedSafetyBench improves their medical safety. By introducing this new benchmark dataset, our work enables a systematic study of the state of medical safety in LLMs and motivates future work in this area, thereby mitigating the safety risks of LLMs in medicine.
6/14/2024